Neutropenia Treatment Market to hit USD 20.8 billion by 2032, says Global Market Insights Inc.
November 04, 2024 02:30 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Neutropenia Treatment Market size is projected to be worth USD 20.8 billion by the end of 2032. The increasing prevalence of cancer...
[Latest] Global Acute Respiratory Infection Market Size/Share Worth USD 20,796.6 Billion by 2033 at a 1.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
October 29, 2024 12:30 ET
|
Custom Market Insights
Austin, TX, USA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Acute Respiratory Infection Market Size, Trends and Insights By Drug Type...
Antibiotics Market Size to Surpass USD 65.23 Billion by 2032, with 3.70% CAGR – SNS Insider
October 23, 2024 09:00 ET
|
SNS Insider pvt ltd
Austin, Oct. 23, 2024 (GLOBE NEWSWIRE) -- According to SNS Insider, The Antibiotics Market Size was valued at USD 47.23 Billion in 2023 and is projected to reach USD 65.23 Billion by 2032, growing...
Antibiotic Resistance Research Report 2024: 6 Key Large Opportunities in this Space and Developed Market Forecasts with Profiles of 100+ Biotechnology Companies
October 15, 2024 10:31 ET
|
Research and Markets
Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides &...
Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024
October 14, 2024 07:31 ET
|
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024
Pseudarthrosis Treatment Market is Projected to Reach $1.37 Billion at a CAGR 4.6% by 2034 | Fact.MR Report
September 05, 2024 06:00 ET
|
FACT.MR
Rockville, MD, Sept. 05, 2024 (GLOBE NEWSWIRE) -- According to a new industry report released by Fact.MR, revenue from the global pseudarthrosis treatment market is estimated to reach US$ 879.4...
Antibiotics Strategic Business Report 2024: Rising Demand in Emerging Economies Accelerates Demand, Narrow-Spectrum Antibiotics Spurs Innovation in Targeted Therapy - Forecast to 2030
August 01, 2024 09:40 ET
|
Research and Markets
Dublin, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The "Antibiotics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Antibiotics is...
Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency Against Indicated Pathogens
July 31, 2024 07:30 ET
|
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline)
Antibacterial Drugs Research - Global Strategic Business Report to 2030 Featuring Allergan, AstraZeneca, Bayer, BMS, GSK, Johnson & Johnson, Merck, Novartis, Pfizer,
July 26, 2024 06:27 ET
|
Research and Markets
Dublin, July 26, 2024 (GLOBE NEWSWIRE) -- The "Antibacterial Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Antibacterial...
Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia
July 18, 2024 07:30 ET
|
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA®